A method for the treatment or alleviation of 3alpha-hydroxy-5alpha/beta-steroid induced central nervous system (“CNS†) disorders in human patients, wherein at least one compound selected from the group consisting of 3beta,20alpha-dihydroxy-5beta-pregnane, 3beta,20alpha-dihydroxy-5beta-pregnane, 3beta,21-dihydroxy-5beta-pregnan-20-one, 3beta-hydroxy-5alpha-pregnan-11,20-dione, and 3beta-hydroxy-5alpha-pregnan-20-one-acetate, is administered to said human patient.
›2.↳ 1The method of claim 1, wherein said at least one compound is administered in the form of a pharmaceutical composition further comprising at least one …d2
The method of claim 1, wherein said at least one compound is administered in the form of a pharmaceutical composition further comprising at least one carrier.
›3.↳ 1The method of claim 1, wherein said at least one compound is in the form of a sodium salt.d2
The method of claim 1, wherein said at least one compound is in the form of a sodium salt.
›4.↳ 1The method of claim 1, wherein said at least one compound is administered to said human patient intravenously, nasally, per rectum, intravaginally, pe…d2+2
The method of claim 1, wherein said at least one compound is administered to said human patient intravenously, nasally, per rectum, intravaginally, percutaneously or orally.
›5.↳ 4The method of claim 4, wherein said at least one compound is administered to said human patient intravenously.d3
The method of claim 4, wherein said at least one compound is administered to said human patient intravenously.
›6.↳ 4The method of claim 4, wherein said at least one compound is administered nasally.d3
The method of claim 4, wherein said at least one compound is administered nasally.
›7.↳ 1The method of claim 1, wherein said at least one compound is administered to said human patient intravenously in doses in the interval of about 0.2 to…d2
The method of claim 1, wherein said at least one compound is administered to said human patient intravenously in doses in the interval of about 0.2 to about 200 mg per kg body weight.
›8.↳ 1The method of claim 1, wherein said at least one compound is administered intravenously in doses in the interval of about 20 to about 100 mg per kg bo…d2
The method of claim 1, wherein said at least one compound is administered intravenously in doses in the interval of about 20 to about 100 mg per kg body weight.
›9.↳ 1The method of claim 1, wherein said steroid-induced CNS-disorder is a steroid related mood disorder.d2
The method of claim 1, wherein said steroid-induced CNS-disorder is a steroid related mood disorder.
›10.↳ 1The method of claim 1, wherein said steroid-induced CNS-disorder is a side effect of postmenopausal hormone therapy in human patients.d2
The method of claim 1, wherein said steroid-induced CNS-disorder is a side effect of postmenopausal hormone therapy in human patients.
›11.↳ 1The method of claim 1, wherein said steroid-induced CNS-disorder is a side effect of oral contraceptives in human patients.d2
The method of claim 1, wherein said steroid-induced CNS-disorder is a side effect of oral contraceptives in human patients.
›12.↳ 1The method of claim 1, wherein said steroid-induced CNS-disorder is steroid-related tiredness in human patients.d2
The method of claim 1, wherein said steroid-induced CNS-disorder is steroid-related tiredness in human patients.
›13.↳ 1The method of claim 1, wherein said steroid-induced CNS-disorder is a steroid-related memory disturbance in human patients.d2
The method of claim 1, wherein said steroid-induced CNS-disorder is a steroid-related memory disturbance in human patients.
›15.↳ 1The method of claim 1, wherein said 3alpha-hydroxy-5alpha/beta-steroid induced disorder is selected from the group consisting of: epilepsy, migraine, …d2+2
The method of claim 1, wherein said 3alpha-hydroxy-5alpha/beta-steroid induced disorder is selected from the group consisting of: epilepsy, migraine, depression, eating disorders, cognitive disorders, movement disorders, sleeping disorders, stress related disorders, menstrual cycle linked disorders, premenstrual syndrome, premenstrual dysphoric disorder; substance dependence, menstrual cycle linked epilepsy; and combinations thereof.
›18.↳ 15The method of claim 15, wherein said 3alpha-hydroxy-5alpha/beta-steroid induced disorder is a menstrual cycle linked disorder selected from the group …d3
The method of claim 15, wherein said 3alpha-hydroxy-5alpha/beta-steroid induced disorder is a menstrual cycle linked disorder selected from the group consisting of: sedation, tiredness, memory disturbance, learning disturbance, concentration difficulties, disturbance of motor function, clumsiness, increased appetite and food cravings, negative mood as tension, irritability and depression, premenstrual syndrome, premenstrual worsening of Petit Mal epilepsy, stress sensitivity, concentration difficulties, loss of impulse control and depression and combinations thereof.
›19.↳ 15The method of claim 15, wherein said 3alpha-hydroxy-5alpha/beta-steroid induced disorder is a stress related disorder selected from the group consisti…d3
The method of claim 15, wherein said 3alpha-hydroxy-5alpha/beta-steroid induced disorder is a stress related disorder selected from the group consisting of: stress related mood changes, depression, migraine, tiredness, memory changes, sedation, memory disturbance, learning disturbance, concentration difficulties, disturbance of motor function, clumsiness, increased appetite and food cravings, negative mood as tension, irritability and depression, worsening of Petit Mal epilepsy, stress sensitivity, concentration difficulties, loss of impulse control, substance dependence, stress related epilepsy, stress related worsening of Alzheimer's dementia, post partum mood changes and combinations thereof.
›16.↳ 1The method of claim 1, wherein the compound is 3beta,21-dihydroxy-5beta-pregnan-20-one.d2
The method of claim 1, wherein the compound is 3beta,21-dihydroxy-5beta-pregnan-20-one.
